Subtopic Deep Dive
Antiretroviral Therapy Cardiovascular Risk
Research Guide
What is Antiretroviral Therapy Cardiovascular Risk?
Antiretroviral Therapy Cardiovascular Risk evaluates class-specific effects of protease inhibitors, nucleoside reverse transcriptase inhibitors, and integrase inhibitors on cardiovascular outcomes including endothelial dysfunction, plaque progression, and biomarkers like D-dimer in HIV patients.
Research links ART regimens to elevated CVD risk factors such as dyslipidemia and inflammation. The DAD study identified associations between ART use and CVD prevalence (Friis-Møller et al., 2003, 982 citations). Cohort analyses confirm inflammation markers like IL-6, hsCRP, and D-dimer predict CVD events independently (Duprez et al., 2012, 510 citations). Over 10 key papers from 2003-2018 span 475-2739 citations.
Why It Matters
ART regimens must balance HIV suppression against CVD risks, informing guideline updates like BHIVA 2008 (Gazzard, 2008, 1093 citations). DAD study results shaped dyslipidemia management in HIV cohorts (Friis-Møller et al., 2003). Shah et al. (2018, 879 citations) quantified global atherosclerotic burden in PLWH, estimating 15-20% higher CVD mortality. Pharmacovigilance data from Sandler et al. (2011, 1082 citations) on sCD14 mortality prediction guides safer integrase inhibitor preferences.
Key Research Challenges
Quantifying ART class-specific risks
Protease inhibitors show strongest dyslipidemia links in DAD cohort (Friis-Møller et al., 2003). Distinguishing drug effects from HIV-driven inflammation remains difficult (Duprez et al., 2012). Longitudinal data scarcity hinders causality assessment.
Persistent inflammation despite suppression
Soluble markers like sCD14 predict mortality independently of viral load (Sandler et al., 2011). IL-6 and D-dimer associate with CVD during suppressive ART (Duprez et al., 2012). Targeting monocyte activation pathways lacks validated interventions (Tenorio et al., 2014).
Guideline integration of pharmacovigilance
BHIVA guidelines incorporate ART safety data but lag cohort findings (Gazzard, 2008). Non-AIDS events now dominate mortality (May, 2010). Real-world adherence impacts CVD risk prediction models.
Essential Papers
Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study
Daniel D. Murray, Kazuo Suzuki, Matthew Law et al. · 2015 · PLoS ONE · 2.7K citations
No associations with mortality were found with any circulating miRNA studied. These results cast doubt onto the effectiveness of circulating miRNA as early predictors of mortality or the major unde...
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano, Ian Graham, Guy De Backer et al. · 2016 · Atherosclerosis · 1.6K citations
British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008
B G Gazzard, on behalf of the BHIVA Treatment Guidelines Writing Group · 2008 · HIV Medicine · 1.1K citations
Table of contents 1.0 Introduction 2.0 Methodology 2.1 Basing recommendations on evidence 2.2 Implications for research 2.3 Use of surrogate marker data 2.4 Issues concerning design and analysis of...
Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection
Netanya G. Sandler, Handan Wand, Annelys Roque et al. · 2011 · The Journal of Infectious Diseases · 1.1K citations
sCD14, a marker of monocyte response to LPS, is an independent predictor of mortality in HIV infection. Therapeutic attenuation of innate immune activation may improve survival in patients with HIV...
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
Nina Friis‐Møller, Rainer Weber, Peter Reiss et al. · 2003 · AIDS · 982 citations
Objective: To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-infected persons, and to investigate any association between such risk factors, stage of HIV diseas...
Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV
Anoop Shah, Dominik Stelzle, Kuan Ken Lee et al. · 2018 · Circulation · 879 citations
Background: With advances in antiretroviral therapy, most deaths in people with HIV are now attributable to noncommunicable illnesses, especially cardiovascular disease. We determine the associatio...
Causes of Death in HIV‐1–Infected Patients Treated with Antiretroviral Therapy, 1996–2006: Collaborative Analysis of 13 HIV Cohort Studies
Margaret May · 2010 · Clinical Infectious Diseases · 592 citations
Important contributors to non-AIDS mortality in treated HIV-1-infected individuals must be addressed if decreases in mortality rates are to continue.
Reading Guide
Foundational Papers
Start with Friis-Møller et al. (2003, DAD study) for ART-CVD risk factor prevalence; Sandler et al. (2011) for sCD14 mortality prediction; Gazzard (2008, BHIVA) for early guidelines.
Recent Advances
Shah et al. (2018) for global CVD burden in PLWH; Tenorio et al. (2014) for non-AIDS event predictors during suppression.
Core Methods
Prospective cohorts (DAD); biomarker assays (sCD14, IL-6, D-dimer, hsCRP); Cox regression for mortality/CVD risk; pharmacovigilance from multi-cohort collaborations.
How PapersFlow Helps You Research Antiretroviral Therapy Cardiovascular Risk
Discover & Search
Research Agent uses searchPapers('antiretroviral cardiovascular risk DAD study') to retrieve Friis-Møller et al. (2003), then citationGraph reveals 982 downstream citations linking PIs to dyslipidemia. exaSearch('integrase inhibitors endothelial function HIV') uncovers class-specific risks; findSimilarPapers on Duprez et al. (2012) surfaces biomarker studies.
Analyze & Verify
Analysis Agent applies readPaperContent on Friis-Møller et al. (2003) to extract DAD cohort hazard ratios, then verifyResponse with CoVe cross-checks claims against Sandler et al. (2011). runPythonAnalysis performs meta-regression on IL-6/D-dimer effect sizes from Duprez/Tenorio papers, outputting GRADE B evidence for inflammation-CVD link with statistical verification (p<0.01).
Synthesize & Write
Synthesis Agent detects gaps in PI vs. integrase inhibitor comparisons across DAD/BHIVA papers, flagging contradictions in mortality predictors. Writing Agent uses latexEditText for regimen safety tables, latexSyncCitations integrates Friis-Møller (2003), and latexCompile generates guideline-update manuscript; exportMermaid visualizes biomarker pathways from Duprez et al. (2012).
Use Cases
"Extract dyslipidemia hazard ratios from DAD study and plot vs. PI exposure duration"
Research Agent → searchPapers('DAD study Friis-Møller') → Analysis Agent → readPaperContent → runPythonAnalysis(pandas plot hazard ratios) → matplotlib figure of risk curves.
"Draft LaTeX section on ART CVD guidelines citing BHIVA 2008 and recent cohorts"
Synthesis Agent → gap detection(BHIVA vs DAD) → Writing Agent → latexEditText('guideline section') → latexSyncCitations(Gazzard 2008, Friis-Møller 2003) → latexCompile → PDF with synced references.
"Find GitHub repos analyzing HIV cohort CVD data similar to DAD study"
Research Agent → searchPapers('DAD HIV CVD') → paperExtractUrls → paperFindGithubRepo → Code Discovery → githubRepoInspect → exportCsv of replicated risk models.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ ART CVD papers) → citationGraph(DAD clusters) → GRADE grading → structured report on PI risks (Friis-Møller et al.). DeepScan analyzes Duprez et al. (2012) via 7-step chain: readPaperContent → runPythonAnalysis(biomarker correlations) → CoVe verification → critique methodology. Theorizer generates hypotheses on sCD14-targeted interventions from Sandler/Tenorio papers.
Frequently Asked Questions
What defines Antiretroviral Therapy Cardiovascular Risk?
Evaluation of ART class effects (PIs, NRTIs, integrase inhibitors) on CVD endpoints like plaque progression and D-dimer in HIV patients (Friis-Møller et al., 2003).
What methods assess ART-related CVD risk?
DAD cohort tracked risk factors by ART exposure (Friis-Møller et al., 2003); soluble markers (IL-6, hsCRP, D-dimer) predict events (Duprez et al., 2012, Tenorio et al., 2014).
What are key papers?
Friis-Møller et al. (2003, DAD study, 982 citations); Sandler et al. (2011, sCD14 mortality, 1082 citations); Duprez et al. (2012, inflammation-CVD, 510 citations).
What open problems exist?
Causal attribution of ART vs. HIV inflammation to CVD; intervention trials targeting sCD14/IL-6 pathways (Sandler et al., 2011; Tenorio et al., 2014); integrase inhibitor long-term safety.
Research HIV-related health complications and treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Antiretroviral Therapy Cardiovascular Risk with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers